Bausch + Lomb Corporation Stock Price, News & Analysis

Bausch + Lomb (NYSE/TSX: BLCO) reported strong Q2 2024 results with revenue of $1.216 billion, up 17% as reported and 20% on a constant currency basis compared to Q2 2023. The company experienced broad-based growth across all business segments. Key highlights include:

- Vision Care revenue: $697 million, up 8% (11% constant currency)
- Surgical revenue: $209 million, up 7% (9% constant currency)
- Pharmaceuticals revenue: $310 million, up 60% (61% constant currency)

However, the company reported a GAAP net loss of $151 million. Adjusted EBITDA (non-GAAP) was $209 million, up from $179 million in Q2 2023. Based on strong performance, Bausch + Lomb raised its full-year 2024 revenue and Adjusted EBITDA guidance.

Bausch + Lomb (NYSE/TSX: BLCO), a prominent global eye health company, is set to release its second-quarter 2024 financial results on July 31, 2024. The company will hold a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All relevant materials will be available on the Investor Relations section of the Bausch + Lomb website before the call. The webcast can be accessed via the provided link, and participants can join the call using the provided dial-in numbers and access code. A replay will be available until August 14, 2024.

Bausch + Lomb (NYSE/TSX: BLCO) revealed results from their inaugural State of Dry Eye survey, highlighting widespread dry eye symptoms among Americans and a lack of awareness about the condition. The survey underscores that dry eye is increasingly prevalent, particularly among younger individuals due to modern lifestyles and extensive digital device use. Key findings include that 75% of sufferers find symptoms extremely bothersome, and 67% have had to alter their daily activities. Despite these impacts, 70% of Americans are unaware of prevention or treatment options, and 43% do not regularly see an eye doctor. To address this, Bausch + Lomb launched KnowYourDryEye.com to provide education and facilitate dialogues between sufferers and eye care professionals. Untreated dry eye can worsen and lead to more serious eye problems, making awareness and early intervention crucial.

Bausch + Lomb (NYSE/TSX: BLCO), a global leader in eye health, announced the presentation of new data at the European Dry Eye Society (EuDEC) 2024 Congress in Madrid, Spain, from June 20-22. The event will feature multiple scientific presentations and educational sessions focusing on patient-centric approaches to dry eye disease. Key presentations include studies on preservative-free formulations, ocular vasoconstrictors, treatment landscapes, and the use of narrative medicine in understanding the disease's impact on quality of life. Notable sessions will cover innovations in clinical diagnosis, technological advancements, and patient communication.

Bausch + Lomb has introduced its new INFUSE for Astigmatism daily disposable contact lenses in the U.S. These lenses, designed with ProBalance Technology™ and OpticAlign® design, offer clear, stable vision and all-day comfort. The lenses address common issues for astigmatic patients, including dryness and blurred vision exacerbated by digital device use. The lenses feature kalifilcon A material that provides high moisture (55%) and breathability (107 Dk/t). They will be available to eye care professionals starting July 2024.

INFUSE for Astigmatism includes osmoprotectants, electrolytes, and moisturizers for a 16-hour wearing experience. A study showed 97% of these lenses had less than three degrees of rotation with blink. They also provide clear vision across the entire power range and reduce spherical aberration, halos, and glare. Additionally, Bausch + Lomb offers a recycling program for used contact lens materials.

Bausch + Lomb (NYSE/TSX: BLCO) has launched Blink NutriTears, a new clinically proven over-the-counter supplement for dry eyes in the U.S. This product targets the root causes of dry eyes and promotes healthy tear production, providing relief within two to four weeks. The supplement contains lutein, zeaxanthin, curcumin, and vitamin D, shown to improve ocular symptoms and tear film homeostasis. Clinical studies indicate NutriTears can keep tears on the eyes 33% longer, offering significant symptom relief. It will be available in the eye care aisle and online at major retailers by the end of July.

Bausch + Lomb, a global eye health company, announced the results of its 2024 annual shareholder meeting held on May 29, 2024. All 10 nominated directors were elected. Key votes included Nathalie Bernier, Gary Hu, Brett Icahn, Sarah B. Kavanagh, Karen L. Ling, John A. Paulson, Russel C. Robertson, Thomas W. Ross Sr., Brenton L. Saunders, and Andrew C. von Eschenbach.

Shareholders approved executive compensation in a non-binding advisory vote and an amendment to the 2022 Omnibus Incentive Plan, increasing the number of shares authorized for issuance. PricewaterhouseCoopers LLP was appointed as the independent registered public accounting firm until the 2025 annual meeting. The final vote results will be filed with the SEC on Form 8-K and will be available on the company's SEDAR+ profile and website.

Bausch + Lomb announced the presentation of new scientific data at the American Optometric Association's Optometry’s Meeting. Scheduled events include 12 ePosters and 3 live presentations, highlighting products like MIEBO, Blink NutriTears, and INFUSE. Key presentations will cover clinical data on Blink Triple Care Lubricating Eye Drops and Biotrue Hydration Plus Multi-Purpose Solution. The company will also host nine educational events. MIEBO and XIIDRA's benefits for dry eye disease and other eye health products will be discussed.

Bausch + Lomb (NYSE/TSX: BLCO) has received Health Canada approval for its new enVista® Envy™ intraocular lens (IOL), marking the first global regulatory approval of this product. The enVista Envy IOL offers a full visual range with high tolerance to dysphotopsia. Clinical trials in Canada showed excellent long-term outcomes, with 93% of patients reporting minimal visual disturbances and 94% experiencing little to no difficulty viewing close objects while achieving excellent distance vision without glasses. The lens features ActivSync Optic Intelligent Energy Distribution and ClearPath technology, enhancing vision in varying lighting conditions and reducing light scattering. Commercial availability in Canada is set for mid-June, with plans for additional regulatory approvals in the U.S. and Europe.